Cargando…

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1

Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Isakson, Sara H., Rizzardi, Anthony E., Coutts, Alexander W., Carlson, Daniel F., Kirstein, Mark N., Fisher, James, Vitte, Jeremie, Williams, Kyle B., Pluhar, G. Elizabeth, Dahiya, Sonika, Widemann, Brigitte C., Dombi, Eva, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Stemmer-Rachamimov, Anat O., Fahrenkrug, Scott C., Gutmann, David H., Giovannini, Marco, Moertel, Christopher L., Largaespada, David A., Watson, Adrienne L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168575/
https://www.ncbi.nlm.nih.gov/pubmed/30302402
http://dx.doi.org/10.1038/s42003-018-0163-y
_version_ 1783360378269335552
author Isakson, Sara H.
Rizzardi, Anthony E.
Coutts, Alexander W.
Carlson, Daniel F.
Kirstein, Mark N.
Fisher, James
Vitte, Jeremie
Williams, Kyle B.
Pluhar, G. Elizabeth
Dahiya, Sonika
Widemann, Brigitte C.
Dombi, Eva
Rizvi, Tilat
Ratner, Nancy
Messiaen, Ludwine
Stemmer-Rachamimov, Anat O.
Fahrenkrug, Scott C.
Gutmann, David H.
Giovannini, Marco
Moertel, Christopher L.
Largaespada, David A.
Watson, Adrienne L.
author_facet Isakson, Sara H.
Rizzardi, Anthony E.
Coutts, Alexander W.
Carlson, Daniel F.
Kirstein, Mark N.
Fisher, James
Vitte, Jeremie
Williams, Kyle B.
Pluhar, G. Elizabeth
Dahiya, Sonika
Widemann, Brigitte C.
Dombi, Eva
Rizvi, Tilat
Ratner, Nancy
Messiaen, Ludwine
Stemmer-Rachamimov, Anat O.
Fahrenkrug, Scott C.
Gutmann, David H.
Giovannini, Marco
Moertel, Christopher L.
Largaespada, David A.
Watson, Adrienne L.
author_sort Isakson, Sara H.
collection PubMed
description Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies.
format Online
Article
Text
id pubmed-6168575
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61685752018-10-09 Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 Isakson, Sara H. Rizzardi, Anthony E. Coutts, Alexander W. Carlson, Daniel F. Kirstein, Mark N. Fisher, James Vitte, Jeremie Williams, Kyle B. Pluhar, G. Elizabeth Dahiya, Sonika Widemann, Brigitte C. Dombi, Eva Rizvi, Tilat Ratner, Nancy Messiaen, Ludwine Stemmer-Rachamimov, Anat O. Fahrenkrug, Scott C. Gutmann, David H. Giovannini, Marco Moertel, Christopher L. Largaespada, David A. Watson, Adrienne L. Commun Biol Article Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies. Nature Publishing Group UK 2018-10-02 /pmc/articles/PMC6168575/ /pubmed/30302402 http://dx.doi.org/10.1038/s42003-018-0163-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Isakson, Sara H.
Rizzardi, Anthony E.
Coutts, Alexander W.
Carlson, Daniel F.
Kirstein, Mark N.
Fisher, James
Vitte, Jeremie
Williams, Kyle B.
Pluhar, G. Elizabeth
Dahiya, Sonika
Widemann, Brigitte C.
Dombi, Eva
Rizvi, Tilat
Ratner, Nancy
Messiaen, Ludwine
Stemmer-Rachamimov, Anat O.
Fahrenkrug, Scott C.
Gutmann, David H.
Giovannini, Marco
Moertel, Christopher L.
Largaespada, David A.
Watson, Adrienne L.
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
title Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
title_full Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
title_fullStr Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
title_full_unstemmed Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
title_short Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
title_sort genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168575/
https://www.ncbi.nlm.nih.gov/pubmed/30302402
http://dx.doi.org/10.1038/s42003-018-0163-y
work_keys_str_mv AT isaksonsarah geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT rizzardianthonye geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT couttsalexanderw geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT carlsondanielf geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT kirsteinmarkn geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT fisherjames geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT vittejeremie geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT williamskyleb geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT pluhargelizabeth geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT dahiyasonika geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT widemannbrigittec geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT dombieva geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT rizvitilat geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT ratnernancy geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT messiaenludwine geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT stemmerrachamimovanato geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT fahrenkrugscottc geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT gutmanndavidh geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT giovanninimarco geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT moertelchristopherl geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT largaespadadavida geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1
AT watsonadriennel geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1